[{"orgOrder":0,"company":"Rznomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"RZ-001","moa":"hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rznomics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Not Applicable"},{"orgOrder":0,"company":"Rznomics","sponsor":"Charles River","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"RZ-001","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rznomics \/ Charles River","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Charles River"},{"orgOrder":0,"company":"Rznomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"RZ-001","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rznomics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Not Applicable"},{"orgOrder":0,"company":"Rznomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"RZ-001","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rznomics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Not Applicable"},{"orgOrder":0,"company":"GenVivo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"GVO-1102","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"GenVivo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GenVivo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GenVivo \/ Not Applicable"},{"orgOrder":0,"company":"Rznomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"RZ-001","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Rznomics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Not Applicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Private Placement","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Viracta Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ BVF Partners"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Sunesis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Merger","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Sunesis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Sunesis Pharmaceuticals"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Sunesis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Merger","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Sunesis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Sunesis Pharmaceuticals"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Preclinical","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rznomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"RZ-001","moa":"||hTERT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Rznomics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals for Valganciclovir
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
